-
公开(公告)号:US11337985B2
公开(公告)日:2022-05-24
申请号:US17406689
申请日:2021-08-19
IPC分类号: A61K31/551 , A61P25/14 , A61K31/198
摘要: Pharmaceutical composition for use in the prophylactic and/or therapeutic treatment of dyskinesias induced by L-DOPA. The present invention relates to the pharmaceutical field, more particularly to the use of Rho kinase inhibitors for treating or preventing dyskinesias induced by L-DOPA.
-
公开(公告)号:US20220071917A9
公开(公告)日:2022-03-10
申请号:US16760527
申请日:2018-11-02
发明人: María José Alonso Fernandez , Desireé Teijeiro Osorio , Carmen María Teijeiro Valiño , Ana Cadete Pires
IPC分类号: A61K9/51 , C07K16/22 , A61K39/395 , A61K47/62 , A61K47/69
摘要: The present invention generally relates to particles, including nanocapsules or other nanoentities, comprising a polymer such as polysialic acid. The particles are able to access the interior of the cells, and/or to procure the intracellular release of the associated drugs. In 5 one aspect, the present invention is directed to nanocapsules or other entities having an exterior or surface comprising a polymer such as polysialic acid. In some cases, targeting moieties such as Lyp-1 or tLyp-1 peptide are bonded to the polymer, e.g., using aminoalkyl (C1-C4) succinimide or other linkers. These may be created, for example, by reacting a carboxylate moiety on a polymer with an aminoalkyl maleimide (C1-C4) or an aminoalkyl 10 (C1-C4) methacrylamide, and reacting the resulting aminoalkyl (C1-C4) maleimide or the aminoalkyl (C1-C4) methacrylamide to a cysteine or other sulfur group. Targeting moieties are bonded to the polymer, for example, by reacting a carboxylate moiety on a polymer with a N-hydroxysuccinimide or a carbodiimide, and reacting the intermediate formed with a lysine or arginine group on a targeting peptide to produce polymer-amide-peptide. Other 15 aspects of the invention are generally directed to methods of making or using such compositions, kits including such compositions, or the like.
-
公开(公告)号:US20210393646A1
公开(公告)日:2021-12-23
申请号:US17406689
申请日:2021-08-19
IPC分类号: A61K31/551 , A61K31/198 , A61P25/14
摘要: Pharmaceutical composition for use in the prophylactic and/or therapeutic treatment of dyskinesias induced by L-DOPA. The present invention relates to the pharmaceutical field, more particularly to the use of Rho kinase inhibitors for treating or preventing dyskinesias induced by L-DOPA.
-
公开(公告)号:US11149209B2
公开(公告)日:2021-10-19
申请号:US16632623
申请日:2018-07-20
摘要: The present invention refers to process for oxidation of organosulfur compounds comprising metal AQCs having between 5 and 13 metal atoms as catalyst. Additionally, the present invention refers to the use of the metal AQCs having between 5 and 13 metal atoms as catalyst in the oxidation of organosulfur compounds and to a chemical composition comprising organosulfur compounds and metal AQCs having between 5 and 13 metal atoms.
-
公开(公告)号:US10725050B2
公开(公告)日:2020-07-28
申请号:US15759321
申请日:2016-09-09
申请人: UNIVERSIDADE DE SANTIAGO DE COMPOSTELA , SERVIZO GALEGO DE SAUDE (SERGAS) , FUNDACIÕN INSTITUTO DE INVESTIGACIÓN SANITARIA DE SANTIAGO DE COMPOSTELA
发明人: Manuela Alonso Sampedro , Victor Álvarez González , Cristóbal Colón Mejeras , Miguel A. García González , Olaya Lamas González
摘要: The present invention is comprised in the field of glycobiology. In particular, it relates to a method for separating, in biological samples, the fraction bound to or associated with sulfated glycosaminoglycans (GAGs), and the applications thereof in biomedicine, such as for identifying the profile of glycoproteins or the profile of lipids bound to or associated with sulfated GAGs, detecting an alteration in the pattern of glycosylation by sulfated GAGs, identifying biomarkers for the diagnosis, for the prognosis, for monitoring the progression of a disease or of the effect of a therapy, or for identifying compounds suitable for the treatment of a disease. The invention also relates to methods for diagnosing mucopolysaccharidosis and for diagnosing and determining the prognosis of a kidney disease.
-
公开(公告)号:US20200054647A1
公开(公告)日:2020-02-20
申请号:US16348589
申请日:2017-11-10
发明人: Jessica RODRÍGUEZ VILLAR , José Luis MASCAREÑAS CID , José RODRÍGUEZ COUCEIRO , Jesús MOSQUERA MOSQUERA , Marcos Eugenio VÁZQUEZ SENTÍS , Bruno SAINZ ANDING
IPC分类号: A61K31/555 , A61P35/00
摘要: The present invention relates to the use of ruthenium(II) complexes for preparing a medicinal product for treating cancer, particularly cancer comprising cancer stem cells. Said ruthenium complexes are capable of selectively metallating guanine quadruplexes, thus resulting in increased expression of the c-MYC oncogene. This increase in the proportion of c-MYC may promote the differentiation of cancer stem cells.
-
公开(公告)号:US10471020B2
公开(公告)日:2019-11-12
申请号:US15350653
申请日:2016-11-14
IPC分类号: A61K9/51 , A61K31/7088 , A61K38/28
摘要: The present invention generally relates to particles, including nanoparticles, for example, for drug delivery or other applications. Certain aspects of the present invention are generally directed to particles, such as nanoparticles, comprising an inner portion and a coating. The inner portion may contain insulin or other therapeutic molecules for delivery to a living organism. In some cases, the molecules may be electrostatically complexed with an oppositely-charged peptide, such as an oligoarginine, or other species. The therapeutic molecules may also be water soluble. In some cases, the peptide may be conjugated to a hydrophobic portion, such as cholesterol, lauric acid, or a fatty acid chain. This hydrophobic modification may facilitate complex formation with the therapeutic molecule and the stability of the resulting complex. The complex typically is surrounded by a coating, which may protect the complex. For example, the coating may include polymers such as poly(glutamic acid) and poly(ethylene glycol). In some cases, the coated complex may also facilitate transport across cells, e.g., within the gastrointestinal tract. Other aspects of the invention are generally directed to methods of making or using such compositions, kits including such compositions, or the like.
-
公开(公告)号:US10253000B2
公开(公告)日:2019-04-09
申请号:US15301127
申请日:2015-03-03
发明人: Ma del Carmen Terán Moldes , Pedro Besada Pereira , Tamara Costas Caamaño , Ma del Carmen Costas Lago , Noemí Vila Molares , Dolores Viña Castelao
IPC分类号: C07D237/14 , A61P25/28 , A61K31/50 , A61K31/501 , A61K31/5377 , A61K45/06
摘要: The present invention refers to pyridazin-3(2H)-one derivatives of general structure I, II and III, which are selective MAO-B inhibitors, and to the use thereof for preparing medicaments intended to treat disorders derived from MAO-B hyperactivity, particularly degenerative disorders of the central nervous system (CNS), such as Parkinson's disease (PD), Alzheimer's disease (AD) and other dementias. These are pyridazin-3(2H)-one derivatives having dithiocarbamate moieties bonded to position 4, 5 or 6 through an alkyl chain of variable length (n=1, 2, 3). This invention is also directed to the preparation of said compounds.
-
公开(公告)号:US20180371138A1
公开(公告)日:2018-12-27
申请号:US16062536
申请日:2016-12-14
IPC分类号: C08F220/60 , C08F220/34
摘要: The present invention refers to a novel screening method for transfection employing novel acryloyl based amphiphilic polymers.
-
10.
公开(公告)号:US20180328939A1
公开(公告)日:2018-11-15
申请号:US15759321
申请日:2016-09-09
申请人: UNIVERSIDADE DE SANTIAGO DE COMPOSTELA , SERVIZO GALEGO DE SAUDE (SERGAS) , FUNDACIÓN INSTITUTO DE INVESTIGACIÓN SANITARIA DE SANTIAGO DE COMPOSTELA
发明人: Manuela ALONSO SAMPEDRO , Víctor ÁLVAREZ GONZÁLEZ , Cristóbal COLÓN MEJERAS , Miguel A. GARCÍA GONZÁLEZ , Olaya LAMAS GONZÁLEZ
摘要: The present invention is comprised in the field of glycobiology. In particular, it relates to a method for separating, in biological samples, the fraction bound to or associated with sulfated glycosaminoglycans (GAGs), and the applications thereof in biomedicine, such as for identifying the profile of glycoproteins or the profile of lipids bound to or associated with sulfated GAGs, detecting an alteration in the pattern of glycosylation by sulfated GAGs, identifying biomarkers for the diagnosis, for the prognosis, for monitoring the progression of a disease or of the effect of a therapy, or for identifying compounds suitable for the treatment of a disease. The invention also relates to methods for diagnosing mucopolysaccharidosis and for diagnosing and determining the prognosis of a kidney disease.
-
-
-
-
-
-
-
-
-